Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 06 2021
Historique:
received: 22 05 2020
accepted: 21 05 2021
entrez: 11 6 2021
pubmed: 12 6 2021
medline: 25 2 2023
Statut: epublish

Résumé

To assess adherence to standard clinical practice for the diagnosis and treatment of patients undergoing prostate cancer (PCa) radiotherapy in four European countries using clinical audits as part of the international IROCA project. Multi-institutional, retrospective cohort study of 240 randomly-selected patients treated for PCa (n = 40/centre) in the year 2015 at six European hospitals. Clinical indicators applicable to general and PCa-specific radiotherapy processes were evaluated. All data were obtained directly from medical records. The audits were performed in the year 2017. Adherence to clinical protocols and practices was satisfactory, but with substantial inter-centre variability in numerous variables, as follows: staging MRI (range 27.5-87.5% of cases); presentation to multidisciplinary tumour board (2.5-100%); time elapsed between initial visit to the radiation oncology department and treatment initiation (42-102.5 days); number of treatment interruptions ≥ 1 day (7.5-97.5%). The most common deviation from standard clinical practice was inconsistent data registration, mainly failure to report data related to diagnosis, treatment, and/or adverse events. This clinical audit detected substantial inter-centre variability in adherence to standard clinical practice, most notably inconsistent record keeping. These findings confirm the value of performing clinical audits to detect deviations from standard clinical practices and procedures.

Identifiants

pubmed: 34112863
doi: 10.1038/s41598-021-91723-0
pii: 10.1038/s41598-021-91723-0
pmc: PMC8192927
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12323

Références

Can J Urol. 2005 Oct;12(5):2808-15
pubmed: 16274516
Cancer Radiother. 2015 Oct;19(6-7):621-3
pubmed: 26321683
Phys Med Biol. 2003 Jan 21;48(2):139-55
pubmed: 12587901
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S80-4
pubmed: 18406944
Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):243-50
pubmed: 12118558
Radiother Oncol. 2007 Feb;82(2):191-200
pubmed: 17267059
Radiat Oncol. 2020 Aug 27;15(1):208
pubmed: 32854730
Radiat Oncol. 2016 Jun 08;11:78
pubmed: 27276878
Radiother Oncol. 2018 Feb;126(2):183-190
pubmed: 28988660
Radiother Oncol. 2018 May;127(2):161-163
pubmed: 29548562
J Natl Cancer Inst. 2013 Jan 16;105(2):113-21
pubmed: 23274388
J Clin Oncol. 2010 Dec 10;28(35):5160-5
pubmed: 20956628
Transl Oncol. 2018 Jun;11(3):794-799
pubmed: 29704788
Anticancer Res. 2013 Apr;33(4):1629-33
pubmed: 23564807
Radiother Oncol. 2011 Apr;99(1):29-36
pubmed: 21458094
J Urol. 2003 Jan;169(1):157-63
pubmed: 12478126
Lancet Oncol. 2011 Apr;12(4):387-98
pubmed: 21463833
BJU Int. 2015 Jun;115(6):907-12
pubmed: 24612460
Asian Pac J Cancer Prev. 2013;14(5):2829-34
pubmed: 23803039
J Med Imaging Radiat Oncol. 2015 Apr;59(2):255-64
pubmed: 25345594
Can Urol Assoc J. 2012 Apr;6(2):121-7
pubmed: 22511420
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61
pubmed: 17467926
J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121
pubmed: 29030906
Radiother Oncol. 2014 Aug;112(2):194-8
pubmed: 25245556
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Radiother Oncol. 2008 Apr;87(1):3-16
pubmed: 18160158
J Natl Compr Canc Netw. 2018 May;16(5S):620-623
pubmed: 29784740
Eur Urol. 2013 Dec;64(6):895-902
pubmed: 23541457
Oncology (Williston Park). 2018 Oct 17;32(10):501-4
pubmed: 30334240
Radiol Oncol. 2014 Apr 25;48(2):210-8
pubmed: 24991212
Breast. 2011 Apr;20 Suppl 2:S70-4
pubmed: 21316239
Phys Med. 2016 Dec;32(12):1551-1558
pubmed: 27890566
Rep Pract Oncol Radiother. 2017 Sep-Oct;22(5):408-414
pubmed: 28831281
Cancer. 2014 Jun 15;120(12):1787-93
pubmed: 24604289
Clin Transl Radiat Oncol. 2018 Jul 06;12:28-33
pubmed: 30094353
Psychooncology. 2014 Aug;23(8):841-54
pubmed: 24846702
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):841-842
pubmed: 29485058
Laryngoscope. 2015 Mar;125(3):624-9
pubmed: 25220657
Jpn J Clin Oncol. 2008 Nov;38(11):723-9
pubmed: 18952706
Scand J Public Health. 2017 May;45(3):230-237
pubmed: 28443490
J Glob Oncol. 2016 Aug 10;3(3):242-249
pubmed: 28717766

Auteurs

Carla Lopes de Castro (C)

Instituto Português de Oncologia, Porto, Portugal. carlalopescastro@gmail.com.
Department of Radiation Oncology, Instituto Português de Oncologia Francisco Gentil-Porto, Porto, Portugal. carlalopescastro@gmail.com.

Magdalena Fundowicz (M)

Greater Poland Cancer Centre, Poznan, Poland.

Alvar Roselló (A)

Institut Català d'Oncologia, Girona, Spain.

Josep Jové (J)

Institut Català d'Oncologia, Badalona, Spain.

Letizia Deantonio (L)

Università degli Studi del Piemonte Orientale (UNIUPO), Novara, Italy.

Artur Aguiar (A)

Instituto Português de Oncologia, Porto, Portugal.

Carla Pisani (C)

Università degli Studi del Piemonte Orientale (UNIUPO), Novara, Italy.

Salvador Villà (S)

Institut Català d'Oncologia, Badalona, Spain.

Anna Boladeras (A)

Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain.

Ewelina Konstanty (E)

Greater Poland Cancer Centre, Poznan, Poland.

Marta Kruszyna-Mochalska (M)

Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Greater Poland Cancer Centre, Poznan, Poland.

Piotr Milecki (P)

Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Greater Poland Cancer Centre, Poznan, Poland.

Diego Jurado-Bruggeman (D)

Institut Català d'Oncologia, Girona, Spain.

Joana Lencart (J)

Instituto Português de Oncologia, Porto, Portugal.

Ignasi Modolell (I)

Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain.

Carles Muñoz-Montplet (C)

Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain.

Luisa Aliste (L)

Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain.

Maria Gloria Torras (MG)

Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain.

Montserrat Puigdemont (M)

Institut Català d'Oncologia, Girona, Spain.

Luísa Carvalho (L)

Instituto Português de Oncologia, Porto, Portugal.

Marco Krengli (M)

Università degli Studi del Piemonte Orientale (UNIUPO), Novara, Italy.

Ferran Guedea (F)

Institut Català d'Oncologia, L'Hospitalet, Barcelona, Spain.

Julian Malicki (J)

Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Greater Poland Cancer Centre, Poznan, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH